FDA orphan drug designations for lysosomal storage disorders - a cross-sectional analysis.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

United States Food and Drug Administration*/legislation & jurisprudence; Lysosomal Storage Diseases/*drug therapy ; Orphan Drug Production/*statistics & numerical data; Cross-Sectional Studies ; Databases, Pharmaceutical ; Drug Discovery ; Government Regulation ; Humans ; Orphan Drug Production/legislation & jurisprudence ; Tripeptidyl-Peptidase 1 ; United States

Purpose: To provide a quantitative clinical-regulatory insight into the status of FDA orphan drug designations for compounds intended to treat lysosomal storage disorders (LSDs).
Methods: Assessment of the drug pipeline through analysis of the FDA database for orphan drug designations with descriptive and comparative statistics.
Results: Between 1983 and 2019, 124 orphan drug designations were granted by the FDA for compounds intended to treat 28 lysosomal storage diseases. Orphan drug designations focused on Gaucher disease (N = 16), Pompe disease (N = 16), Fabry disease (N = 10), MPS II (N = 10), MPS I (N = 9), and MPS IIIA (N = 9), and included enzyme replacement therapies, gene therapies, and small molecules, and others. Twenty-three orphan drugs were approved for the treatment of 11 LSDs. Gaucher disease (N = 6), cystinosis (N = 5), Pompe disease (N = 3), and Fabry disease (N = 2) had multiple approvals, CLN2, LAL-D, MPS I, II, IVA, VI, and VII one approval each. This is an increase of nine more approved drugs and four more treatable LSDs (CLN2, MPS VII, LAL-D, and MPS IVA) since 2013. Mean time between orphan drug designation and FDA approval was 89.7 SD 55.00 (range 8-203, N = 23) months.
Conclusions: The drug development pipeline for LSDs is growing and evolving, with increased focus on diverse small-molecule targets and gene therapy. CLN2 was the first and only LSD with an approved therapy directly targeted to the brain. Newly approved products included "me-too"-enzymes and innovative compounds such as the first pharmacological chaperone for the treatment of Fabry disease.
Competing Interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: SG, SK, and CS have no potential conflicts of interest to declare with respect to the research, authorship, and/or publication of this article. KM has served as investigator in clinical trials conducted by Emalex, Gedeon Richter, Lundbeck, Shire, Sunovion and Teva, plus in European Union funded projects. GFH received lecturing fees from Danone and Takeda. EM has received honoraria and/or consulting fees from Actelion, Alexion, BioMarin, Orphazyme, Sanofi Genzyme, and Shire. MR received consultancy fees or research grants from Alexion, GSK, Oxyrane and Shire. EM is managing partner of SphinCS GmbH, a private clinical research institute, which had research grants from Sanofi Genzyme, Takeda, Alexion, Orphazyme and Idorsia. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Clin Pharmacol Drug Dev. 2019 Nov;8(8):984-994. (PMID: 30650260)
J Inherit Metab Dis. 2019 Mar;42(2):295-302. (PMID: 30693535)
N Engl J Med. 2009 Jan 29;360(5):447-58. (PMID: 19179314)
Orphanet J Rare Dis. 2015 Apr 17;10:45. (PMID: 25896637)
Macromol Biosci. 2019 Aug;19(8):e1900130. (PMID: 31222941)
N Engl J Med. 2014 Oct 16;371(16):1507-17. (PMID: 25317870)
Genet Med. 2019 Oct;21(10):2208-2215. (PMID: 30899093)
J Inherit Metab Dis. 2018 Sep;41(5):877-883. (PMID: 29110179)
Genet Med. 2019 Feb;21(2):347-352. (PMID: 29875421)
PLoS One. 2016 Dec 9;11(12):e0166948. (PMID: 27935997)
Mol Ther. 2006 Jun;13(6):1031-49. (PMID: 16624621)
Orphanet J Rare Dis. 2017 Jun 17;12(1):113. (PMID: 28623936)
Nucleic Acids Res. 2011 Jan;39(1):359-72. (PMID: 20699274)
Clin Pharmacol Ther. 2018 Apr;103(4):703-711. (PMID: 28699267)
Pediatr Endocrinol Rev. 2016 Jun;13 Suppl 1:689-96. (PMID: 27491217)
Nat Biotechnol. 2012 May;30(5):460-5. (PMID: 22484455)
N Engl J Med. 2016 Aug 11;375(6):545-55. (PMID: 27509102)
Lancet. 2017 Oct 14;390(10104):1758-1768. (PMID: 28803710)
N Engl J Med. 2018 May 17;378(20):1898-1907. (PMID: 29688815)
Assay Drug Dev Technol. 2011 Jun;9(3):213-35. (PMID: 21612550)
Nat Rev Mol Cell Biol. 2013 Jan;14(1):49-55. (PMID: 23169466)
Pediatrics. 2000 Jan;105(1):e10. (PMID: 10617747)
J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):332-40. (PMID: 16763896)
Mol Ther. 2018 Sep 5;26(9):2304-2314. (PMID: 30025991)
Methods Mol Biol. 2016;1478:145-160. (PMID: 27730579)
Hum Genet. 1999 Jul-Aug;105(1-2):151-6. (PMID: 10480370)
Eur J Hum Genet. 2004 Feb;12(2):87-92. (PMID: 14685153)
Nature. 2010 Sep 16;467(7313):318-22. (PMID: 20844535)
Expert Opin Biol Ther. 2019 Jul;19(7):655-670. (PMID: 31056978)
Mol Ther. 2014 Nov;22(11):2004-12. (PMID: 25052852)
Genet Med. 2018 Apr;20(5):524-530. (PMID: 29048419)
J Natl Cancer Inst. 2000 Jan 19;92(2):98-100. (PMID: 10639505)
PLoS One. 2016 Jan 06;11(1):e0144973. (PMID: 26735955)
N Engl J Med. 1991 May 23;324(21):1464-70. (PMID: 2023606)
Genet Med. 2017 Sep;19(9):983-988. (PMID: 28383542)
JAMA. 1999 Jan 20;281(3):249-54. (PMID: 9918480)
Annu Rev Biomed Eng. 2015;17:63-89. (PMID: 26643018)
Orphanet J Rare Dis. 2015 Apr 18;10:46. (PMID: 25896727)
Science. 2014 Nov 28;346(6213):1258096. (PMID: 25430774)
Science. 2013 Feb 15;339(6121):823-6. (PMID: 23287722)
PLoS One. 2013;8(1):e54459. (PMID: 23365668)
J Inherit Metab Dis. 2019 Sep;42(5):975-983. (PMID: 31222755)
J Inherit Metab Dis. 2017 May;40(3):343-356. (PMID: 28314976)
PLoS Med. 2007 Oct 16;4(10):e297. (PMID: 17941715)
Cell. 2017 Jan 12;168(1-2):20-36. (PMID: 27866654)

Date Created: 20200409 Date Completed: 20200706 Latest Revision: 20211204

20240105

PMC7141691

10.1371/journal.pone.0230898

32267884